TVTX - חוב כולל להון Travere Corp

Risks for Travere Therapeutics (TVTX) are linked to Filspari promotion costs and expensive research, which pressure capital. This price action chart on GURU.Markets captures a leverage ratio of 24.67, highlighting financial stability driven by drug exclusivity and steady cash flow. Business development relies on alliances with universities and global laboratories to support patients.

This ratio serves as a critical filter during position stress-testing, determining the extent of the business's reliance on borrowed funds relative to its equity. By analyzing the trend of the total debt-to-equity ratio, an investor assesses liquidity risk, which for Travere Therapeutics (TVTX) is mitigated by the inelastic demand for Filspari and the ability to exercise pricing power due to its orphan drug status.